TrialCancer2021

Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.

Keunchil Park et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.